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Trivalent influenza vaccine in patients 
on haemodialysis: impaired 
seroresponse with differences for 
A-H3N2 and A-H1N1 vaccine 
components 
W.E.P. Beyer*, D.J. Versluis*, P. Kramer*, Ph.P.M.N. Diderich**, W. 
Weimar* and N. Masurel* 
One hundred and one patients on haemodialysis, 21 patients on peritoneal dialysis and 30 healthy 
controls received a trivalent split vaccine containing 15 gg haemagglutinin ofa recent influenza A- 
H3N2, influenza A-H1NI and influenza B strain, respectively. Antibody production after four 
weeks was determined by the haemagglutination-inhibition estand expressed as response rate, 
protection rate and overall mean fold increase. The patients on haemodialysis revealed a 
diminished seroresponse, ascompared to patients on peritoneal dialysis and controls. For influenza 
A-H3N2, this was less distinct han for the other two antigens. In patients on haemodialysis the 
protection rate was 66% against he A-H3N2 vaccine component (versus 85% in controls, not 
significant), but only 25% against A-H1N1 and27% against B (versus 84 and 77% in controls, p < 
0.001). Duration of haemodialysis up to eight years did not affect seroresponse. Patients on 
haemodialysis who were primed for influenza A.H1N1 in the period 1947-1957, reacted markedly 
better to the A-H1N1 vaccine component than subjects of other priming periods. A booster injection 
of the same vaccine dosage four weeks after the first immunization, performed in 98 patients on 
haemodialysis, was of little value: it had virtually no effect with regard to influenza A-HIN1 and 
influenza B, and showed, though significantly better, still poor results for A-H3N2. The differences 
in seroresponse between the A-H3N2 and A-H1N1 vaccine component suggest a major defect of 
primary, and a minor defect of secondary humoral response in patients on haemodialysis. The 
consequences for vaccine policy in these patients are discussed. 
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Introduction 
Patients with chronic renal disorders may benefit from 
annual vaccination against influenza A and B viruses as 
excess mortality due to epidemic influenza has been 
reported in this group 1. Protection provided by inacti- 
vated whole virus, split or subunit influenza vaccines is 
mainly associated with the evocation of high antibody 
titres against viral haemagglutinin (HA)2; the role of 
simultaneously stimulated cellular immunity is less 
clear. Patients with chronic renal failure have an 
impaired cellular and humoral immunity (for review 
see 3) which might also affect seroresponsiveness to 
vaccines. The immunogenicity of influenza vaccine has 
• • 45 been studied in patients with glomerular diseases • and 
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patients on haemodialysis 5-8, and also in kidney trans- 
plant recipients 7'9-13. While the safety of the vaccine in 
these patient groups was established, varying results 
were obtained in reaching a satisfactory humoral res- 
ponse. However, in most studies small numbers of 
patients were involved. Recently, an evidently 
impaired seroresponse to influenza vaccine has been 
described in 4014 and 2915 patients on haemodialysis. In
the present study, the anti-HA-antibody production of 
trivalent influenza vaccine in a large number of patients 
on haemodialysis has been evaluated. The influence of 
the patients' age and the duration of the dialysis treat- 
ment on antibody response was studied. 
Materials and methods 
Study population 
One hundred and sixty five subjects were included in 
the study. The group of patients on intermittent main- 
tenance haemodialysis (HD) consisted of 108 patients 
(53 males and 55 females), aged 17 to 76 years. In 18 
patients (17%), the underlying disorder leading to 
ends*age renal failure was of immunological origin• 
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Haemodialysis had started 1 month to 13 years before. 
For comparison, 26 patients undergoing continuous 
ambulatory peritoneal dialysis (PD) were studied. This 
group consisted of 14 males and 12 females, aged 23 to 
73 years. An underlying immunological disorder had 
caused renal failure in 9 patients (35%). Dialysis had 
started 2 months to 12 years before. None of the HD or 
PD patients received immunosuppressive drugs at the 
time of vaccination. All patients were in a stable con- 
dition. 3l healthy volunteers (15 males, 16 females, age 
range 19-69 years) served as controls for the immuno- 
genicity of the vaccine. 
Vaccine, dosage, administration, vaccination 
regimen 
0.5 ml of a trivalent influenza split vaccine for the 
season 1985-1986 (Alorbat, Asta-Werke, Frankfurt/ 
Main, FRG, lot no. 075104) containing 15 lag HA of 
A/Philippines/2/82 (H3N2), A/Chile/I/83 (H1N1) and 
B/USSR/100/83, respectively, was administered by 
intramuscular injection in the upper arm on day 0 (first 
immunization) and on day 30 (booster immunization). 
Sera were obtained on day 0 (SO, prevaccination), day 
30 ($30) and day 60 ($60). The study was performed in 
The Netherlands in the absence of naturally occurring 
influenza in the autumn of 1985. 
Laboratory investigations and calculations 
Sera were separated immediately after blood collec- 
tion and clotting and kept frozen at -20°C until tit- 
ration. Influenza virus strains identical to the vaccine 
components (kindly provided by Dr J.J. Skehel, WHO 
World Influenza Centre, London, UK) were propa- 
gated in embryonated 10 to 12-day-old chicken eggs. 
Because of the low avidity of the influenza B virus, 
infectious egg fluids of this strain were treated with 
ether according to Berlin et al. 1~, and the watery phase 
was used in the serologic tests. 
Serum haemagglutination-inhibition (HI) titres were 
17 determined twice by standard methods simulta- 
neously in pre- and postvaccination sera. Titres were 
expressed as the reciprocals of the dilution showing 
50% haemagglutination inhibition with 3 haemaggluti- 
nation units of the antigen. From the results of the two 
determinations per serum and per antigen, the geo- 
metric means were used for further calculations. Nega- 
tive titres (<9) were arbitrarily regarded as 5. 
With the method used, protection against infection is 
associated with an HI-titre of 100 against influenza 
A 18"19 and 200 for ether-treated influenza B 2°. Separa- 
tely for each antigen, subjects who had a prevaccination 
titre above these thresholds, were excluded. The results 
of the previously unprotected individuals were used for 
calculation of the following measures. (1) Response 
rate, i.e. the proportion of subjects who showed a 
fourfold or greater titre rise after vaccination. (2) 
Protection rate, i.e. the proportion of subjects exceed- 
ing the threshold titre of 100 (influenza A) and 200 
(influenza B) respectively, after vaccination. (3) Over- 
all mean fold increase (MFI), i.e. the difference 
between the logarithmic (logm) geometric mean titres 
of post- and prevaccination sera. Differences in qualita- 
tive measures were tested for significance by the X 2 test 
and in quantitative measures by the Wilcoxon rank test. 
Results 
Final groups and clinical reactions 
Twenty one subjects did not complete the full course 
of the vaccination scheme because of performance of a 
renal transplantation (one HD patient and three PD 
patients), development of dialysis-associated peritonitis 
(six PD patients), death for reasons unrelated to the 
vaccination (three HD patients) or unknown reasons 
(six HD patients and two control subjects). One 
hundred and one HD patients, 21 PD patients and 30 
control subjects completed the first vaccination (SO + 
$30), and 98 HD patients, 17 HD patients and 29 
control subjects the booster vaccination (S0 + $30 + 
$60). No major clinical side effects of the vaccine were 
reported. 
Seroresponse to first vaccination 
The height of prevaccination titres was inversely 
related to the height of titre rises after vaccination (not 
shown). After exclusion of subjects with already pro- 
tective prevaccination titres for each antigen separa- 
tely, the HD and PD groups and the control group were 
tested for differences with regard to geometric means 
of prevaccination titres, male/female ratio and age. No 
significant differences were found, and the groups were 
regarded as comparable. 
As shown in Table 1, the control subjects produced 
satisfying protection and response rates ranging from 
77 to 95% . Results of PD patients were inferior to 
controls, but no statistical difference could be detected, 
except for the MFI value for the A-H3N2 component 
(1.35 versus 1.79, p = 0.02) and the protection rate for 
the A-H1N1 component (47% versus 84% , p = 0.01). 
In contrast, the patients on haemodialysis showed a 
significant impairment for all three vaccine compo- 
nents: only 67, 43 and 56% of 101 HD patients howed 
Table 1 Response rates, protection rates and mean fold increase (MFI) values in control subjects and patients on peritoneal dialysis (PD) and on 
haemodialysis (HD), after first vaccination 
Parameter A-H3N2 A-H 1 N 1 B 
Controls PD HD Controls PD HD Controls PD HD 
Subjects included/ 
subjects vaccinated a 20/30 18/21 73/101 25/30 19/21 91/101 26/30 
Loglo GMT SO b 1.14 1.20 1.10 1.12 0.96 1.09 1.16 
Response rate (number, %) 19(95%) 15(83%)  49(67%)* 21 (84%)  9(47%)** 39(43%)*** 21(86%) 
Protection rate (number, %) 17(85%) 17(94%)  48(66%)1" 21(84%) 15(79%)  23(25%) 1~/~1  20(77%) 





1.20 ± 0.65 0.75 _+ 0.64 ~-** 
aNumber of subjects after exclusion of those with protective prevaccination titres (/> 100, influenza A; >i 200, influenza B)/total number of subjects 
vaccinated. %ogarithmic geometric mean titre of prevaccination sera. Significant differences between groups by ,%2 test (response rate, protection rate) or 
Wilcoxon-test (MFI): *p < 0.05, **p < 0.01, ***p < 0.001 versus controls, tp < 0.05, l-tp < 0.01, t t tp  < 0.001 versus PD 
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Table 2 Complete nonresponders among control subjects and patients on peritoneal dialysis (PD) and on haemodialysis (HD), after first vaccination 
Parameter Control PD HD 
Number of subjects unprotected against all three vaccine components prior to immunization/total number 
of subjects vaccinated 16/30 14/21 61/101 
Complete nonresponders after first vaccination -/16(0%) -/14/(0%) 13/61(21%)* 
Subjects remaining unprotected after first vaccination 1/16(6%) 1/14(7%) 15/61(25%) 
*p < 0.05 versus controls 
a fourfold or greater titre rise and only 66, 25 and 27% 
obtained protective titres against influenza A-H3N2, 
A-H1N1 and B, respectively. This impairment was less 
distinct for A-H3N2 than for A-HIN1 and B. 
The significance of these findings is stressed by the 
calculation of complete nonresponders (Table 2). Sixty 
one HD patients were not protected against all three 
influenza strains prior to immunization. Of these, still 
13 (21%) did not respond to any of the three vaccine 
components and 15 (25%) remained unprotected 
against all three viruses after the first vaccination. In 
contrast, no complete nonresponders could be found 
among 14 PD patients and 16 controls. 
Variables influencing seroresponse in dialysis 
patients 
The following variables were tested for influencing 
the responsiveness to the vaccine components in the 
various groups: duration of dialysis treatment, age, sex 
and etiology of renal disease (immunological or not). 
The latter two did not show any influence. Figure 1 
presents the seroresponse of HD patients, expressed as 
increases in individual titres related to the duration of 
haemodialysis in years. The distribution remained con- 
stant during the first 8 years. The few patients with a 
longer duration of dialysis more frequently produced 
higher titre increases, similar to healthy controls. 
Therefore, in Table 3, the serological response is sum- 
marized for two classes of HD patients (up to 8 years 
versus more than 8 years of haemodialysis). Again, 
there were no significant differences between these 
classes in respect of male/female ratio, age, prevaccina- 
tion titres or etiology of renal failure. Indeed, the 
patients maintained on HD for more than 8 years 
achieved response and protection rates similar to con- 
trol subjects, while the rates in the classes with shorter 
duration were lower. This phenomenon was present for 
all three antigens, but most distinct for A-H1N1. 
A similar analysis for peritoneal dialysis was not 
appropriate as there was only one PD patient (after 
exclusion of subjects with high prevaccination titres) 
whose dialysis treatment had started more than 8 years 
ago. In the other subjects no correlation between 
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Figure 1 Individual increase in pre- and postvaccination titres among patients on haemodialysis after first vaccination, related to duration of 
haemodialysis. Increase in titre is expressed as log ($30) - log (SO). C, control subjects• - - - - ,  Threshold of nonresponders (increase less than fourfold) 
and responders (increase fourfold or greater), a, influenza A-H3N2; b, influenza A-H1N1; c, influenza B 
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Table 3 Response rates, protection rates, and mean fold increase (MFI) values in patients on haemodialysis (HD) after first vaccination. Differences 
between duration of haemodialysis ~<8 years and >8 years 
Parameter A-H3N2 A-H1 N1 B 
HD ~< 8 HD > 8 p value HD ~< 8 HD > 8 p value HD ~< 8 HD > 8 p value 
years years years years years years 
Subjects included a 66 7 84 7 78 6 
Log GMT SO b 1.09 1.29 n.s. 1.10 1.13 n.s. 1.32 0.88 n.s. 
Response rate 
(number, %) 43(65%) 6(86%) n.s. 33(39%) 6(86%) <0.05 18(23%) 6(100%) <0.001 
Protection rate 
(number, %) 42(64%) 6(86%) n.s. 17(20%) 6(86%) <0.001 21(27%) 2(33%) n.s. 
MFI ± s.d. 1.06 _+ 0.75 1.35 _+ 0.60 n.s. 0.51 + 0.49 1.32 ± 0.51 <0.01 0.70 +_ 0.61 1.48 _+ 0.59 <0.05 
aNumber of subjects after exclusion of those with protective prevaccination titres (/> 100, influenza A; >~ 200, influenza B). In total, 101 HD patients were 
vaccinated. ~'See Table 1. n.s., not significant 
duration of peritoneal dialysis and the findings of sero- 
response was found (not shown). 
In the control and PD group, the seroresponse was 
not influenced by the age of the vaccinees. In HD 
patients, however, there was a tendency to a decreasing 
seroresponse with increasing age for all three antigens 
(Figure 2). The age distribution for A-H1N1 in HD 
patients differed markedly from the A-H3N2 and the B 
component in showing a normal seroresponse in sub- 
jects aged 36--45 years reaching response and protec- 
tion rates of 86 and 86% and an MFI of 1.04 (versus 84, 
84% and 1.27, respectively, for controls, not signifi- 
cant). This peak was not due to unequivocal distribu- 
tions of prevaccination titres or other variables in the 
different age cohorts. All other ages responded signifi- 
cantly inferiorly, as is presented in Table 4. For the 
100 - 





a b c 
Figure 2 
subjects; [2], HD, patients on haemodialysis; n, number of subjects 
-<35 46- 55 ~66 <~35 46- 55 ~66 ~<35 46- 55 ~66 
36-45 56-65 36-45 56-65 36-45 56-65 age (years )  
con ~ HD con I - -  HD I con I HD e 
n 20 11 4 15 24 19 25 14 7 13 32 25 26 15 9 12 31 17 
Response rates in different age cohorts of haemodialysis patients, a, Influenza A-H3N2; b, influenza HINI;  c, influenza b. II, con, control 
Table 4 Response rates, protection rates and mean fold increase (MFI) values in patients on haemodialysis after first vaccination. Differences between 
age cohorts 36-45 years and others 
Parameters A-H3N2 A-H1 N1 B 
36-45 36-45 36-45 
years Others c p value years Others p value years Others p value 
Subjects included a 4 69 7 84 9 75 
Log GMT SO ~ 0.96 1.10 n.s. 1.27 1.07 n.s. 1.25 1.29 n.s. 
Response rate 
(number, %) 3(75%) 46(69%) n.s. 6(86%) 33(39%) <0.05 5(56%) 42(56%) n.s. 
Protection rate 
(number, %) 3(75%) 45(65%) n.s. 6(86%) 17(20%) <0.001 3(33%) 20(27%) n.s. 
MFI _+ s.d. 1.33 + 0.54 1.08 + 0.73 n.s. 1.04 + 0.63 0.54 +_ 0.49 <0.05 0.98 +_ 0.79 0.73 ± 0.62 n.s. 
a't~See Table 1. CAge cohorts ~<35 and/>46 years, n.s., not significant 
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Table 5 Effects of booster vaccination in patients on haemodialysis 
Parameter A-H3N2 A-H 1 N 1 B 
Subjects included a 71 88 82 
Subjects protected after booster/subjects unprotected after first vaccination 7/24(29%) 5/66(8%)** 9/60(15%) 
Subjects responding after booster/subjects not responding after first vaccination 10/22(45%) 7/49(14%)** -/35(0%)*** 
aNumber of subjects after exclusion of those with protective prevaccination titres (/>100, influenza A;/>200, influenza B). In total, 98 HD patients received 
a booster vaccination. Significant differences between groups: **p < 0.01; ***p < 0.001 versus A-H3N2 
other two vaccine components, there were no signifi- 
cant differences between the 36-45 year cohort and the 
other ages. 
Effects o f  booster vaccination 
Additional effects of boosting were estimated in 
those subjects who, after first vaccination, did not 
respond or did not achieve protective titre levels. As 
these subjects were scarce in the control and PD group, 
because of the high primary response and protection 
rates (Table 1), analysis was done only for HD patients 
who had received a booster vaccination (Table 5). The 
results were highly dependent on the vaccine compo- 
nents. While the booster effect was poor with regard to 
A-H3N2, revealing protection in only 29% of pre- 
viously unprotected subjects and response in only 45% 
of previously unresponding subjects, it was even signifi- 
cantly less for A-H1N1 (8 and 14%) and B (19 and 
0%). Age, sex, prevaccination titres (SO), etiology of 
renal disease or duration of haemodialysis did not 
influence the boosting effect. 
Discussion 
In this study, persons with high prevaccination titres 
resulting from possible earlier vaccinations or recent 
natural infections were excluded because of the poor or 
absent additional increase of titres in this group 21"22. 
Moreover, it is of major clinical interest to which extent 
immunization leads to a protective state in previously 
unprotected individuals. 
Our results, based on a large number of participants, 
evidently suggest an impaired humoral response to 
trivalent influenza vaccine in patients on intermittent 
maintenance haemodialysis which cannot be satisfac- 
torily compensated by a booster injection of the same 
antigen dosage one month later. This is in accordance 
with Cappel et al. ~4, but not with Jordan et al. ~, Briggs 
et al. 6, Osanloo et al. 5 and Winer et al. 7. However, the 
number of patients in those studies was small and 
subjects with high prevaccination titres were included. 
This might result in underscoring statistically significant 
differences (jype 2 error), as has been demonstrated by 
Gross et al. ~-" for studies dealing with a similar issue 
(influenza vaccination i cancer patients). On the other 
hand, the comparison with vaccination trials performed 
in different years should be made cautiously, since the 
prevalence of prevaccination a tibodies against vaccine 
components, which is a potent factor influencing the 
seroresponse to vaccination, is annually Changing, de- 
pendent on the occurrence of natural influenza seasons. 
Patients on peritoneal dialysis, even those with short 
duration of dialysis, showed a significantly better es- 
ponse than patients on haemodialysis. This issue will be 
discussed in detail elsewhere. 
The duration of haemodialysis treatment was not an 
important factor influencing the seroresponse. Thus, 
the initially poor humoral response of renal endstage 
patients when starting haemodialysis,  not worsened 
or improved by the treatment within the first 8 years. In 
six of seven HD patients with a treatment longer than 8 
years, a significant 'recovery' of seroresponsiveness wa
established. This issue should be subject o longitudinal 
studies including more patients. 
In HD patients, the three vaccine components 
showed remarkable differences in evoking serores- 
ponse. The production of anti-A-H3N2-antibodies was 
least impaired after both first and booster vaccination. 
The influenza B and, even more pronounced, the 
influenza A-H1N1 vaccine component caused less and 
smaller titre rises, as compared to A-H3N2, after first 
vaccination, and had virtually no effect as a booster. 
This could be due to low immunogenicity or an insuf- 
ficient dosage of these two vaccine components or to a 
laboratory artifact (low avidity). However, the control 
subjects revealed results for A-H1N1 and B compar- 
able to the A-H3N2 vaccine component. Alternatively, 
the discrepancy between A-H3N2 and A-H1N1 can be 
explained by a failure of the primary response in HD 
patients. Influenza A subtype H3N2 has been circulat- 
ing since 1968 causing several epidemics with great 
impact. It is likely that most of the HD patients have 
been exposed to A-H3N2 strains before starting the 
dialysis treatment and even before developing severe 
renal failure impairing the immune functions. There- 
fore, the vaccination with the recent A/Philippines/2/ 
82(H3N2) virus, except for its new and strain-specific 
epitopes, is expected to cause an essentially secondary 
response. Influenza A-H1NI strains related to the vac- 
cine component A/Chile/1/83(H1N1) circulated in 
1947-1957. People born between 1939 and 1949 had 
most frequently experienced their first influenza A 
infection by those strains which resulted in a potent 
immunological memory for that particular subtype 
('priming)24. It could be shown that this age cohort 
more frequently produced atypical secondary response 
to a recent A-H1N1 vaccine than the other ages, even 
after three decades 25. Of the HD patients in this study, 
in particular this age cohort (36-45 years) reacted well 
against he A-H1N1 vaccine component. In the other 
age groups, who had not been primed by A-H1N1, the 
reappearance of this subtype in 1977 did not produce a 
significant immunological memory because of its small 
impact in The Netherlands until now. Moreover, most 
of the HD patients had already been in an altered 
immunological state as a result of developing uraemia 
at that time. The data suggest that the A-H1N1 vaccine 
component served as a primary antigen in HD patients 
younger than 36 and older than 45 years and did not 
evoke optimal response. This would be compatible with 
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findings of Boulton-Jones et al. 26 and Byron et al. 27"2a 
suggesting that primary humoral response isprofoundly 
depressed in uraemic patients, while secondary res- 
ponse is less depressed. This conclusion issupported by 
the results of the booster vaccination: in HD patients 
who had not responded to the first immunization, a 
better result was gained against he A-H3N2 compo- 
nent as compared to A-H1N1. 
The HD patients of this study are comparable with 
several other subpopulations within the influenza risk 
group who do not produce protective l vels of anti-HA- 
antibody. Beside uraemic and renal transplant patients 
treated with cyclosporin A 15, these include persons of 
very high age 29'3° and patients with cancer (for review 
see 23). The consequences of these findings for vaccine 
policy in HD patients are unclear. More frequent 
booster vaccinations or increased dosages are, in 
theory, useless in a failing primary humoral immune 
system. We believe that as long as the causes of de- 
pressed humoral response in these patient groups can- 
not be eliminated, the use of amantadine during 
31 ~o influenza A epidemics- and research on live vaccines-- 
and on new generations of vaccine adjuvants 33should 
be stimulated. 
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